• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Andrew D. Norden, MD, MPH


  • Norden AD, Pope WB, Chang SM.Current concepts in brain tumor imaging.Am Soc Clin Oncol Educ Book. 2012:119-24.
  • Rahman R, Hamdan A, Zweifler R, Jiang H, Norden AD, Reardon DA, Mukundan S, Wen PY, Huang RY.Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.J. Neurooncol. 2014 May 8.
  • Lee JW, Norden AD, Ligon KL, Golby AJ, Beroukhim R, Quackenbush J, Wells W, Oelschlager K, Maetzold D, Wen PY.Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: A gene expression imaging study.Epilepsy Res. 2014 Mar 12.
  • Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL.Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.Neuro Oncology. 2014 Apr;16(4):567-78.
  • Chen C, Huang R, MacLean A, Muzikansky A, Mukundan S, Wen PY, Norden AD.Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival.J. Neurooncol. 2013 Nov;115(2):267-76.
  • Zhang JP, Lee EQ, Nayak L, Doherty L, Kesari S, Muzikansky A, Norden AD, Chen H, Wen PY, Drappatz J.Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma.J. Neurooncol. 2013 Oct;115(1):71-7.
  • Huang RY, Rahman R, Hamdan A, Kane C, Chen C, Norden AD, Reardon DA, Mukundun S, Wen PY.Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.Cancer. 2013 Oct 1;119(19):3479-88.
  • Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY.Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.Neuro Oncology. 2013 Jul;15(7):930-5.
  • Rinne ML, Lee EQ, Nayak L, Norden AD, Beroukhim R, Wen PY, Reardon DA.Update on bevacizumab and other angiogenesis inhibitors for brain cancer.Expert Opin Emerg Drugs. 2013 May 14.
  • Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ.Atypical and anaplastic meningiomas treated with bevacizumab.J. Neurooncol. 2012 Aug;109(1):187-93.
  • Craig JM, Vena N, Ramkissoon S, Idbaih A, Fouse SD, Ozek M, Sav A, Hill DA, Margraf LR, Eberhart CG, Kieran MW, Norden AD, Wen PY, Loda M, Santagata S, Ligon KL, Ligon AH.DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues.PLoS ONE. 2012;7(6):e38881.
  • Kesselheim JC, Norden AD, Wen PY, Joffe S.Discontinuing Bevacizumab in Patients with Glioblastoma: An Ethical Analysis.Oncologist. 2011 Sep 23.
  • Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS.Phase II study of Gleevec(®) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.J. Neurooncol. 2011 Sep 22.
  • Norden AD, Bartolomeo J, Tanaka S, Drappatz J, Ciampa AS, Doherty LM, Lafrankie DC, Ruland S, Quant EC, Beroukhim R, Wen PY.Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients.J. Neurooncol. 2011 Jun 26.
  • Young GS, Macklin EA, Setayesh K, Lawson JD, Wen PY, Norden AD, Drappatz J, Kesari S.Longitudinal MRI evidence for decreased survival among periventricular glioblastoma.J. Neurooncol. 2010 Dec 5.
  • Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD.Medical therapies for meningiomas.J. Neurooncol. 2010 Sep;99(3):365-78.
  • Quant EC, Drappatz J, Wen PY, Norden AD.Recurrent high-grade glioma.Curr Treat Options Neurol. 2010 Jul;12(4):321-33.
  • Sure D, Dunn I, Norden A, Anderson WS.Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide.Clin Neurol Neurosurg. 2010 Oct;112(8):741-2.
  • Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE, Wen PY.Phase I Study of Vandetanib with Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma.Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):85-90.
  • Norden AD, Drappatz J, Wen PY, Claus EB.Survival among patients with primary central nervous system lymphoma, 1973-2004.J. Neurooncol. 2010 Jun 17.
  • Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ.Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma.CA Cancer J Clin.;60(3):166-93. Review.
  • Wen PY, Norden AD, Drappatz J, Quant E.Response assessment challenges in clinical trials of gliomas.Curr Oncol Rep. 2010 Jan;12(1):68-75. Review.
  • Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY.Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.J. Neurooncol. 2010 Jan;96(2):211-7.
  • Wen PY,Yung WK,Lamborn KR,Norden AD,Cloughesy TF,Abrey LE,Fine HA,Chang SM,Robins HI,Fink K,Deangelis LM,Mehta M,Di Tomaso E,Drappatz J,Kesari S,Ligon KL,Aldape K,Jain RK,Stiles CD,Egorin MJ,Prados MD.Phase II study of imatinib mesylate (Gleevec(R)) for recurrent meningiomas (North American Brain Tumor Consortium Study 01-08).Neuro-oncol. 2009 Dec;11(6):853-60.
  • Norden AD, Drappatz J, Wen PY.Antiangiogenic therapies for high-grade glioma.Nat Rev Neurol. 2009 Nov;5(11):610-20. Review.
  • Quant EC,Norden AD,Drappatz J,Muzikansky A,Doherty L,Lafrankie D,Ciampa A,Kesari S,Wen PY.Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.Neuro-oncol. 2009 Oct;11(5):550-5.
  • Gerstner ER,McNamara MB,Norden AD,Lafrankie D,Wen PY.Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression.J Neurooncol. 2009 Aug;94(1):97-101.
  • Chi AS, Norden AD, Wen PY.Antiangiogenic strategies for treatment of malignant gliomas.Neurotherapeutics : The Journal Of The American Society For Experimental Neuro Therapeutics. 2009 Jul;6(3):513-26. Review.
  • Norden AD,Drappatz J,Wen PY.Advances in meningioma therapy.Curr Neurol Neurosci Rep. 2009 May;9(3):231-40. Review.
  • Drappatz J,Norden AD,Wen PY.Therapeutic strategies for inhibiting invasion in glioblastoma.Expert Rev Neurother. 2009 Apr;9(4):519-34.
  • Kesari S,Schiff D,Drappatz J,LaFrankie D,Doherty L,Macklin EA,Muzikansky A,Santagata S,Ligon KL,Norden AD,Ciampa A,Bradshaw J,Levy B,Radakovic G,Ramakrishna N,Black PM,Wen PY.Phase II study of protracted daily temozolomide for low-grade gliomas in adults.Clin Cancer Res. 2009 Jan 1;15(1):330-7.
  • Dietrich J,Norden AD,Wen PY.Emerging antiangiogenic treatments for gliomas - efficacy and safety issues.Curr Opin Neurol. 2008 Dec;21(6):736-44. Review.
  • Norden AD,Drappatz J,Muzikansky A,David K,Gerard M,McNamara MB,Phan P,Ross A,Kesari S,Wen PY.An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma.J Neurooncol. 2009 Apr;92(2):149-55.
  • Norden AD,Drappatz J,Wen PY.Novel anti-angiogenic therapies for malignant gliomas.Lancet Neurol. 2008 Dec;7(12):1152-60. Review.
  • Norden AD,Drappatz J,Wen PY.Antiangiogenic therapy in malignant gliomas.Curr Opin Oncol. 2008 Nov;20(6):652-61. Review.
  • Bracht LK,Wen P,Meyerhardt JA,Kulke MH,Hornick JL,Redston M,LaFrankie DC,Black PM,Kesari S,Norden A,Drappatz J.DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor.J Clin Oncol. 2008 Oct 10;26(29):4843-4.
  • Norden AD,Drappatz J,Ciampa AS,Doherty L,LaFrankie DC,Kesari S,Wen PY.Colon perforation during antiangiogenic therapy for malignant glioma.Neuro-oncol. 2009 Feb;11(1):92-5.
  • Drappatz J,Wong ET,Schiff D,Kesari S,Batchelor TT,Doherty L,Lafrankie DC,Ramakrishna N,Weiss S,Smith ST,Ciampa A,Zimmerman J,Ostrowsky L,David K,Norden A,Barron L,Sceppa C,Black PM,Wen PY.A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):222-7.
  • Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY.Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.Neurology. 2008 Mar 4;70(10):779-87.
  • Chi A, Norden AD, Wen PY.Inhibition of angiogenesis and invasion in malignant gliomas.Expert Rev Anticancer Ther. 2007 Nov;7(11):1537-60. Review.
  • Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY.Medical management of brain tumor patients.Neurol Clin. 2007 Nov;25(4):1035-71, ix. Review.
  • Norden AD, Drappatz J, Wen PY.Targeted drug therapy for meningiomas.Neurosurg Focus. 2007 Oct;23(4):E12. Review.
  • Norden AD, Batchelor TT.Reversible posterior leukoencephalopathy syndrome.Onkologie. 2007 Mar;30(3):90-1.
  • Norden AD, Wen PY.Glioma therapy in adults.Neurologist. 2006 Nov;12(6):279-92. Review.
  • Norden AD, Wen PY, Kesari S.Brain metastases.Curr Opin Neurol. 2005 Dec;18(6):654-61.
  • Blumenfeld H, McNally KA, Vanderhill SD, Paige AL, Chung R, Davis K, Norden AD, Stokking R, Studholme C, Novotny EJ, Zubal IG, Spencer SS.Positive and negative network correlations in temporal lobe epilepsy.Cereb Cortex. 2004 Aug;14(8):892-902.
  • Norden AD, Blumenfeld H.The role of subcortical structures in human epilepsy.Epilepsy Behav. 2002 Jun;3(3):219-231.